Kornimate/medical-research-clean huggingface dataset:
engineered tils/car-tils to treat advanced solid tumors

Conditions: Liver Cancer; Lung Cancer; Breast Cancer; Colo-rectal Cancer; Brain Tumor; Solid Tumor, Adult; PD1; CTLA4

Summary: tumor infiltration lymphocytes (tils) have been harvested from advanced cancer patients and constructed to knockout pd1 gene and express scfvs against both pd1 and ctala4 and cars against various antigens, followed by transfusion into the patients. the safety, tolerance, and preliminary clinical efficacy of the tils will be evaluated.

1. choose appropriate patients with advanced lung or other cancers, with written consent for this study; 2. perform biopsy or collect cancerous effusion in thorax or abdomen to obtain tils by standard protocol; 3. grow tils and engineered the tumor-effective tils with crispra-cas9 technique to knockdown pd1 and electronic-transfection strategy to express scfvs that target pd1 and ctla4; amplify the engineered t cells as needed, test the quality and killing activity of the tils and then transfuse them back the patients via systemic or local injections via standard protocol, and follow up closely to collect related parameters as needed; 4. to enhance the killing capability, tumor-noneffective tils have also been genetically engineered to express various cars targeting her2/mesothelin/lewis-y/psca/muc1/ gpc3/axl/egfr/claudin18.2/b7-h3/ror1/gd2/axl/claudin6-dap10 with knockdown of pd1/hpk1 as appropriate; 5. evaluate the clinical results as needed.

Eligibility criteria:
inclusion criteria: 1. patients with advanced cancers that failed to current available therapies; 2. life expectancy \>12 weeks; 3. adequate heart, lung, liver, kidney functions; 4. available for tumor biopsy or cancerous effusions; 5. informed consent explained to, understood by and signed by patient/guardian. patient/guardian given copy of informed consent. exclusion criteria: 1. had accepted gene therapy before; 2. severe virus infection such as hbv, hcv, hiv, et al; known hiv positivity; 3. active infectious disease related to bacteria, virus, fungi, et al; 4. other severe diseases that the investigators consider not appropriate; 5. pregnant or lactating women; 6. systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day); 7. other conditions that the investigators consider not appropriate.

Keywords: liver cancer lung cancer solid tumor til car-til pd1 ctla4 gpc3 mesothelin b7-h3 crispra-cas9
circulating tumour dna as a marker of residual disease & response to adjuvant chemotherapy in stage i-iv ovarian cancer

Conditions: Ovarian Cancer

Summary: to demonstrate that detectable ctdna in peripheral blood following debulking of the primary tumour or following completion of adjuvant treatment for is associated with subsequent disease recurrence in stage i-iv epithelial, fallopian tube and primary peritoneal cancer (ovarian cancer)

this is a prospective,multi-centre study involving serial blood collections from 100 stage i-iv debulked (or to be debulked in the case of neoadjuvant chemotherapy) high grade serous, endometrioid and clear cell ovarian, fallopian tube and primary peritoneal cancer patients (eoc) or ovarian carcinosarcoma planned to receive adjuvant chemotherapy. tumour samples will be made available following patient enrollment for the primary debulking group, and following surgery for the neoadjuvant group for mutation analysis. ascites will not be accepted. up to four blood samples in the primary debulking group and up to five blood samples in the neoadjuvant group will be collected from each patient over a 6-8 month period for ctdna and ca125 analysis choice of chemotherapy will be platinum based treatment at the treating clinician's discretion as per standard of care.

Eligibility criteria:
inclusion criteria: 1. patients that have had primary debulking surgery for curatively resected stage i-iv high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. stage iv patients can only be included in the study if they have had a complete resection of all macroscopic disease with no residual disease. or patients commencing neoadjuvant chemotherapy for stage i- iii high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. women must be planned to undergo interim debulking surgery. 2. a representative tumour sample can be made available for molecular testing after surgery or a core biopsy pre neoadjuvant chemotherapy if available. 3. fit and planned for adjuvant chemotherapy exclusion criteria: 1. history of another primary cancer within the last 3 years 2. patients with epithelial ovarian, fallopian tube and primary peritoneal cancer (eoc) of mucinous subtype and sarcoma 3. patients with stage iv disease who have residual disease 4. patients \<18 years
rhtpo mobilized auto cryo platelets for gyn patients receiving carboplatin

Conditions: Neoplasms, Gynecologic

Summary: a pilot study of transfusion of rhtpo-derived autologous platelets cryopreserved with thrombosol and 2% dmso in patients with gynecologic malignancy receiving carboplatin


Eligibility criteria:
inclusion criteria: * patients with gynecologic malignancy for whom treatment with carboplatin is indicated. * age \>/= 15 years. * adequate hematologic, renal, and hepatic functions. * life expectancy \>/- 3 months. karnofsky performance status \>/= 80. * signed informed consent form. exclusion criteria: * patients with rapidly progressive disease. * pregnant or lactating women. * patients with comorbid condition which renders patients at high risk of treatment complication. * history of cns metastasis. * patients with significant cardiac disease (nyha class iii or iv), dysrhythmia, or recent history of mi or ischemia, transient ischemic attack or cva within the 6 months of study entry. * prior chemotherapy, immunotherapy, any experimental drug within 4 weeks, use of myeloid (g-csf or gm-csf) growth factors within 2 weeks or erythropoietin within 4 weeks. * use of any nitrosourea (bcnu, ccnu) or mitomycin - c within 6 weeks. * prior surgery or rt within 2 wks of study entry. * patients with history of prior high dose chemotherapy with stem cell transplant or with history of prolonged thrombocytopenia (\> 2 weeks). * history of leukemia. * history of any platelet disorders including itp, ttp or bleeding disorders. * history of \> 3 prior chemotherapy regimens (all platinum regimens will be counted as 1 regimen). * demonstrated lack of response to platinum-based therapy.

Keywords: dose-intensified carboplatin autologous cryopreserved platelets thrombopoietin gynecologic malignancy
'real life' monitoring of copd no ics patients

Conditions: COPD

Summary: the aim of the study will be to assess in patients with mild-to-moderate copd the role of inflammation in the patient's therapeutic management and follow-up.

studies have already shown that the risk of severe exacerbations in patients with copd is associated with eosinophilic inflammation (1) and that patients with this type of inflammation have an increased risk of exacerbations if ics administration is discontinued (2), but this indication does not appear in the latest gold recommendations to date. the aim of the study will be to evaluate in patients with mild-to-moderate copd the role of induced sputum and peripheral inflammation in the patient's therapeutic management and follow-up. for this purpose, the investigators will assess inflammation at the bronchial and systemic level by induced sputum and haemochrome at time 0 (recruitment), after 6,12, 18 and 24 months after therapy administration according to the updated 2017 gold recommendations.

Eligibility criteria:
inclusion criteria: * copd diagnosis according to gold 2017 recommendations in clinical stability phase * post bronchodilator fev1 ≥50 and ≤80 * both smoker and ex-smoker * patients on laba or laba/lama therapy * patients also on ics therapy discontinued at least 30 days after enrolment * patient able to cooperate with the required procedures * patient who has signed the informed consent exclusion criteria: * - acute respiratory episode treated with antibiotics and/or steroids in the lower 4 weeks prior to enrolment * patients on roflumilast therapy * any exacerbation of copd within 1 month after visit 1. a patient must not have had any hospitalisation for copd within 6 months prior to visit 1. * comorbidities. history or current evidence of a clinically significant comorbidity or history of a positive test for hiv, hepatitis b or hepatitis c. * history of adverse reactions including immediate or delayed hypersensitivity to any beta2-agonists, * sympathomimetic drugs or any intranasal, inhaled or systemic corticosteroid therapy known or suspected sensitivity to the components of the inhalers used in the study (e.g. lactose in dry powder inhalers). * use of immunosuppressive drugs within 12 weeks prior to visit 1 and during the study, including use of systemic corticosteroids.
abdominal breathing for depression, anxiety, heart rate variability in obstructive sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: the research topic is to explore the effectiveness of abdominal breathing on improving of depression, anxiety, and heart rate variability in obstructive sleep apnea patients with depressive symptoms. this study method adopts an experimental research design and divided into experimental group and control group by random sampling. experimental group receives abdominal breathing training, whereas control group without receiving abdominal breathing training.

obstructive sleep apnea (osa) is a common chronic disease with frequent comorbidity of depression. when we use sedatives, antidepressants or hypnotics for the treatment of depression, these drugs may worsen symptoms of osa leading to aggravation of original depressed moods. therefore, the research topic is to explore the effectiveness of abdominal breathing on improving of depression, anxiety, and heart rate variability among obstructive sleep apnea patients with depressive symptoms. this study method adopts an experimental research design and divided into experimental group and control group by random sampling. experimental group receives abdominal breathing training, whereas control group without receiving abdominal breathing training. the research is conducted with experimental and control groups. the effectiveness assessment will use the beck depression inventory (bdi) beck anxiety inventory (bai) and check the heart rate variability (hrv). both groups received the pre-test before the abdominal breathing training. the post-test was carried out at the fourth and eighth weeks of training. the experimental group is given abdominal breathing training for a total of 8 weeks, with the training in the hospital once a week, 15 minutes for each time, in combination with self-training at home under videos guidance for 10 minutes per day (10 minutes, for one time or several times accumulated) .the expected result is through abdominal breathing, the depression, anxiety, and heart rate variability of osa patients with depressive symptoms can improve, and even with less use of medication.

Eligibility criteria:
inclusion criteria: * aged 20-64 years old. * be able to communicate with chinese and taiwanese, and who can express themselves without barriers. * a person who is clearly conscious and can perform breathing exercises autonomously. * patients diagnosed with obstructive sleep apnea (ahi≧5) according to polysomnography and depression score ≧14 points measured by beck depression inventory-ii (chinese version). exclusion criteria: * patients with copd. * patients with suicidal ideation. * obstructive sleep apnea ahi≧60. * those who have learned abdominal breathing.

Keywords: abdominal breathing obstructive sleep apnea depression anxiety heart rate variability
efficacy and safety of endoscopic papillectomy in the treatment of ampullary neoplasms.

Conditions: Ampullary Adenoma; Ampulla of Vater Adenoma; Ampullary Cancer; Ampulla of Vater Cancer

Summary: the aim of our study is to provide data on the efficacy and safety of endoscopic papillectomy, by including consecutive patients treated after 2015, when first guidelines on endoscopic management of ampullary neoplasms were available.

ampullary neoplasm (an) is a rare disease, but its incidence is increasing. in the last 20 years, endoscopic papillectomy (ep) has become the gold standard treatment for ampullary adenomas and early stage adenocarcinomas, thereby replacing surgical resection, which is burdened by higher rates of morbidity and mortality. however, the data supporting safety and efficacy of ep derive from multiple retrospective studies, that included procedures mostly performed before 2015, when first guidelines on endoscopic management of an were available. this had an impact on large variability in patient selection criteria and endoscopic techniques, resulting in heterogenous outcomes. therefore, the aim of our study is to provide data on the efficacy and safety of this technique, by including consecutive patients treated after the standardization of this technique. all patients who underwent ep at 19 italian centers between january 2016 and december 2021 were included. clinical success was defined by the complete endoscopic management of the neoplasm and any eventual recurrence found in the follow-up period. ep-related adverse events and recurrences were recorded.

Eligibility criteria:
inclusion criteria: * ampullary neoplasm, confirmed by histological examination of the endoscopically resected specimen exclusion criteria: * absence of dysplasia on the resected specimen; * locally advanced or metastatic disease (clinical tnm stage \>t1 or n+ or m+); * neoplasm intra-ductal extension (ide) \> 20 mm; * previously treated ampullary neoplasm.

Keywords: endoscopic papillectomy ampullary adenoma ampullary neoplasm
"ketogenic mediterranean versus hypocaloric balanced diet on polycystic ovarian adolescents"

Conditions: Polycystic Ovary Disease

Summary: study was designed to determine the effect of ketogenic mediterranean diet versus hypocaloric balanced diet on adolescent female with polycystic ovary disease.

this study wsa designed to investigate the effect of the ketogenic mediterranean diet in comparison with hypo-caloric diet on obese adolescent female's patients with polycystic ovary disease trying to find out a new physical therapy approach that had positive effect in the treatment and care for such cases which could enhance the physical therapy field.

Eligibility criteria:
inclusion criteria: 1 - all patients were adolescent females. 2- all patients ages ranged from 16 to 21years old. 3- their bmi ranged from 25kg/m² to 35kg/m². 4- all patients were suffering from hormonal disturbances confirmed by their lab tests and cysts in the ovaries that confirm their diagnosis with polycystic ovary disease. 5- they were conscious and free from any other medical disease. exclusion criteria: patients were examined by a gynecologist before the study and excluded if they have: 1. cardiac problems, epileptics and implanted pacemakers. 2. pregnancy. 3. malignancy and cardiovascular disease. 4. women with skin infection. 5. dysesthesia. 6. cerebrovascular disease. 7. uncontrolled diabetes. 8. severe uncontrolled cardiac patient. 9. liver and kidney dysfunction.
bortezomib, rituximab and dexamethasone (borid) for relapsed/refractory mantle cell lymphoma

Conditions: Lymphoma, Mantle-Cell

Summary: mantle cell lymphoma (mcl) remains difficult to treat by standard treatment approaches. novel drugs have shown promising results in early clinical evaluations. in the current trial, we investigate a combination of bortezomib (a proteasome inhibitor), rituximab (a monoclonal antibody), and dexamethasone in patients with mcl, who have already been pretreated by standard chemotherapy and show again signs of disease progression. the study objectives include remission rates, safety of this drug combination, and survival time.

description of the treatment regimen: bortezomib: 1.3 mg/m2 as i.v. bolus injection, given on days 1, 4, 8, and 11 of each treatment cycle; rituximab: 375 mg/m2 infusion, day 1 of each cycle; dexamethasone: 40 mg per day orally (days 1 - 4) of each treatment cycle. treatment will be given for a total of 6 cycles (every 21 days), followed by maintenance treatment with rituximab (375 mg/m2 every two months for 4 times)

Eligibility criteria:
inclusion criteria: * mantle cell lymphoma at stage ii - iv, previously treated with at least one line of prior therapy (chop or chop-like), measurable disease, age 19 - 75 years, adequate cardiac, liver and renal function tests, patient's written informed consent exclusion criteria: * second malignancy, evidence for cns involvement, clinically significant peripheral neuropathy (grade ii or higher), hiv positivity, pregnancy

Keywords: relapsed or chemotherapy-refractory disease
a feasibility study of mindfulness training transcranial direct current stimulation (tdcs) in adults with overweight and obesity

Conditions: Adults With Overweight and Obesity

Summary: this study will investigate the feasibility of combining an app-based mindfulness training (mt) with at-home administered transcranial direct current stimulation (tdcs) in adults with overweight or obesity and assess whether mt with tdcs may improve weight-related behaviours in this population. specifically, the study will assess whether mt+ active tdcs, as opposed to mt+ sham tdcs or waiting list control, reduces high calorie food craving and consumption. findings will inform the development of a future large-scale randomised controlled trial. the trial will be conducted in the uk.

a randomised controlled feasibility trial with three parallel arms: \[mt + real tdcs\] vs \[mt + sham tdcs\] vs \[waiting list control group\].

Eligibility criteria:
inclusion criteria: * right-handed adults aged 18 to 60 w * overweight or obese (bmi ≥25 kg/ m2) according to world health organisation (who) criteria. * use and understand english as a language for everyday conversation. * have access to a laptop or desktop computer with webcam and to able to attend baseline, post intervention and follow up assessments in the institute of psychiatry, psychology and neuroscience (kcl). exclusion criteria: * insufficient written and spoken english * all known contraindications to tdcs (brunoni et al., 2012) * pregnancy; history of neurological disease and/or seizure * having any metallic implants in the head or body * history of head or eye injury * significant health problems in the previous six months * a lifetime diagnosis of substance dependence, psychosis, bipolar disorder, borderline personality disorder; any other primary psychiatric disorder requiring treatment in its own right * taking psychotropic medication * taking medication for weight loss regular, current or past, mindfulness meditation or yoga practice (defined as \> 20 minutes, twice or more per week during the past 2 months) * consuming more than 14 units of alcohol per week who are unwilling to reduce their alcohol intake for the duration of the treatment * current illicit drug use * learning difficulties that would preclude safe tdcs self-administration and/or completion of questionnaire measures and neurocognitive tasks (e.g.; working memory and inhibitory control) * current atypical anorexia nervosa or purging once a week or more.

Keywords: mindfulness, transcranial direct current stimulation
non-invasive prediction of microvascular invasion in hepatocellular carcinoma by blood-oxygen-level dependent magnetic resonance imaging (bold mri)

Conditions: Hepatocellular Carcinoma

Summary: liver resection and liver transplantation are the acceptable treatment of hepatocellular carcinoma (hcc). but the long-term survival is unsatisfactory as a result of high rate of intra and extra hepatic recurrences. microvascular invasion (mvi) is the most significant risk factor affecting recurrence-free survival in patients following liver resection and liver transplantation. tumor hypoxia (lack of adequate blood supply) is the single most important factor that predict mvi and post surgical prognosis. blood oxygen level dependent (bold) mri is a non-invasive diagnostic method of assessing tumor hypoxia by detecting signal changes secondary to changes in blood flow and oxygenation. bold mri assessment of tumor hypoxia in hcc has never been correlated with pathological confirmation of mvi, the gold standard to assess mvi in hcc. in this study, the investigators propose to assess the ability of bold mri to provide a discriminating quantitative threshold of intratumoral oxygenation predictive of mvi.


Eligibility criteria:
inclusion criteria: * patients with known hepatocellular carcinoma; * scheduled to undergo liver resection or liver transplantation. exclusion criteria: * estimated gfr (egfr \< 30 ml/min; * mri contrast allergy; * general contraindications to mri such as pacemaker, etc.; * prior tumor treatment such as transarterial chemoembolization or the tumor or radiofrequency ablation or chemoradiation; * pregnancy; * age less than 18 years.

Keywords: microvascular invasion blood-oxygen-level dependent magnetic resonance imaging (bold mri)
detection of circulating tumor dna in p16- locally advanced head neck squamous cell carcinoma

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: locally advanced head and neck squamous cell carcinoma (lahnscc) is a heterogeneous disease, associated with a poor prognosis and no improvement in overall survival for years. furthermore, treatments (surgery, radiotherapy, chemotherapy) are frequently associated with acute and late toxicities. beside p16/hpv + tumors, only tnm classification can help estimating the prognosis of the patients. a better evaluation of the prognosis and of the risk of metastatic spread would help defining the best treatment. circulating tumor dna (ctdna) has been reported as both a prognostic factor and a non-invasive way to assess tumor relapse in several cancer types. few data are available in hnscc, and no data among p16/hpv- cancers. indeed, ctdna assessment is usually based on tumor mutation monitoring. but if recurrent mutations are frequent in several cancers types (pik3ca, kras, esr1, tert...), there is no recurrent mutation observed in hnscc. thus ctdna assessment in lahnscc must be performed after the identification of a tumor specific mutation for each patient. in that context, the aim of this study is to perform a molecular analysis of primary lahnscc, and to look for the amount of ctdna before surgery, after surgery, and during 18 months of follow up.

the patients will be enrolled before surgery and follow-up during 18 months. during patient participation, 20 ml of blood will be collected 7 times (before and after surgery, 6 months after diagnosis and every 3 months thereafter until 18 months of follow up). mutation analysis on tumor and healthy tissue will be performed on primary tumors and lymph node dissection, after removal by the surgeon. circulating tumor dna will be detected on blood sample

Eligibility criteria:
inclusion criteria: * operable head and neck squamous cell carcinoma (t3-t4 stage and/or n+) * no p16 expression * curative treatment proposed based on surgery + radiotherapy (+/- chemotherapy) * ps\<3 * written consent signed exclusion criteria: * metastatic spread * previous radiotherapy of head or neck * previous hnscc (except carcinoma restricted to glottis, with a surgery treatment alone and \>3 years of follow up without relapse)

Keywords: circulating tumor dna next generation sequencing digital pcr